Johnson & Johnson reported a 73% response in 15 patients, with no serious treatment-related events at the recommended regimen. The early results are encouraging, but the small study and ongoing Phase 3 trial leave the benefit to be confirmed.
These results give JNJ an encouraging early sign for its prostate cancer program. The study included only 15 patients, and the ongoing Phase 3 trial still needs to test how the combination compares with pasritamig alone.
Follow Johnson & Johnson (JNJ) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for JNJ